GlassScriptPhysician profile
Maxcie M Sikora
NPI 1982886826
$25,153.81
in general payments reported to CMS, 2019-2025
49 companies · $5,934 in 2025
The $5,934 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,824 · 2020: $6,672 · 2021: $2,013 · 2022: $1,907 · 2023: $1,000 · 2024: $1,804 · 2025: $5,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,425 · Consulting Fee: $2,328 · Travel and Lodging: $811 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,424.63 |
| Consulting Fee | $2,328.39 |
| Travel and Lodging | $811.24 |
| Education | $173.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,403.44 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Pfizer INC. | $4,040.38 | 2019-2025 | |
| Genzyme Corporation | $3,336.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,918.48 | 2019-2025 | Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $1,556.81 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,533.97 | 2019-2025 | Dupixent |
| Csl Behring | $1,234.11 | 2019-2025 | Hizentra, Haegarda |
| Genentech USA, INC. | $793.14 | 2019-2025 | Xolair |
| Optinose US, INC. | $388.28 | 2019-2022 | |
| Amgen INC. | $311.90 | 2021-2025 | Tezspire |
| Kaleo, INC. | $268.94 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $263.26 | 2019-2021 | |
| Verona Pharma, INC. | $214.94 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $193.39 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $158.86 | 2020-2025 | Cuvitru, Takhzyro |
Show all 42 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxcie Sikora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.